Compare
3M Co vs Becton Dickinson & Co vs Baxter International Inc vs ResMed Inc
| Latest fiscal year | 3M Co MMM | Becton Dickinson & Co BDX | Baxter International Inc BAX | ResMed Inc RMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-09-30 | 2025-12-31 | 2026-06-30 |
| Revenue | $24.95B | $21.84B | $11.24B | $5.65B |
| Revenue growth (YoY) | +1.5% | +8.2% | +5.7% | +9.9% |
| Gross margin | 39.9% (computed) | 45.4% (computed) | 30.1% | 61.1% |
| Operating margin | 18.6% | 11.8% | -2.7% | 33.4% |
| Net margin | 13.0% | 7.7% | -8.5% | 26.9% |
| Net income | $3.25B | $1.68B | -$957.00M | $1.52B |
| EPS (Diluted) | $6.00 | $5.82 | -$1.87 | $10.43 |
| Operating cash flow | $2.31B | $3.43B | $845.00M | $1.81B |
| Free cash flow | $1.40B | $2.67B | $332.00M | $1.65B |
| Cash & equivalents | n/a | $641.00M | $1.97B | $1.47B |
| Total assets | $37.73B | $55.33B | $20.05B | $8.97B |
| Total liabilities | $32.99B | n/a | $13.95B | $2.38B |
| Shareholders' equity | $4.75B | $25.39B | $6.10B | $6.59B |
| Return on year-end equity | 68.5% | 6.6% | -15.7% | 23.1% |
| Shares outstanding | 530.28M | n/a | n/a | 144.24M |
Revenue, most recent five fiscal years
| Fiscal year | 3M Co | Becton Dickinson & Co | Baxter International Inc | ResMed Inc |
|---|---|---|---|---|
| Latest | $24.95B Ended 2025-12-31 | $21.84B Ended 2025-09-30 | $11.24B Ended 2025-12-31 | $5.65B Ended 2026-06-30 |
| 1 year earlier | $24.57B Ended 2024-12-31 | $20.18B Ended 2024-09-30 | $10.64B Ended 2024-12-31 | $5.15B Ended 2025-06-30 |
| 2 years earlier | $24.61B Ended 2023-12-31 | $19.37B Ended 2023-09-30 | $10.36B Ended 2023-12-31 | $4.69B Ended 2024-06-30 |
| 3 years earlier | $26.16B Ended 2022-12-31 | $18.87B Ended 2022-09-30 | $10.06B Ended 2022-12-31 | $4.22B Ended 2023-06-30 |
| 4 years earlier | $35.35B Ended 2021-12-31 | $19.13B Ended 2021-09-30 | $12.15B Ended 2021-12-31 | $3.58B Ended 2022-06-30 |